Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Boosted by NBC Securities Inc.

NBC Securities Inc. boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 132,300.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,648 shares of the biotechnology company's stock after purchasing an additional 2,646 shares during the period. NBC Securities Inc.'s holdings in Blueprint Medicines were worth $234,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of BPMC. Stephens Inc. AR purchased a new position in shares of Blueprint Medicines during the 4th quarter valued at approximately $321,000. Values First Advisors Inc. grew its holdings in Blueprint Medicines by 277.9% during the 4th quarter. Values First Advisors Inc. now owns 4,970 shares of the biotechnology company's stock worth $433,000 after acquiring an additional 3,655 shares in the last quarter. Van ECK Associates Corp increased its position in shares of Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 363 shares during the last quarter. Asset Management One Co. Ltd. acquired a new stake in shares of Blueprint Medicines in the 4th quarter valued at about $88,000. Finally, State of New Jersey Common Pension Fund D lifted its position in shares of Blueprint Medicines by 12.2% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 25,626 shares of the biotechnology company's stock worth $2,235,000 after purchasing an additional 2,780 shares during the last quarter.

Insider Activity at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of the firm's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. This trade represents a 3.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $101.14, for a total transaction of $505,700.00. Following the completion of the sale, the director now owns 146,630 shares in the company, valued at $14,830,158.20. The trade was a 3.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,574 shares of company stock valued at $1,465,528 over the last 90 days. 4.21% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have commented on BPMC. Jefferies Financial Group initiated coverage on Blueprint Medicines in a report on Monday, March 17th. They set a "buy" rating and a $135.00 target price on the stock. JPMorgan Chase & Co. restated a "neutral" rating and issued a $129.00 price target (down from $130.00) on shares of Blueprint Medicines in a research report on Monday, June 2nd. Wedbush downgraded shares of Blueprint Medicines from an "outperform" rating to a "neutral" rating and boosted their price objective for the company from $128.00 to $129.00 in a research report on Monday, June 2nd. Scotiabank lowered shares of Blueprint Medicines from a "strong-buy" rating to a "sector perform" rating and set a $135.00 price objective on the stock. in a research note on Monday, June 2nd. Finally, Wall Street Zen upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, May 2nd. Seventeen equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $129.35.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded up $0.12 on Monday, hitting $127.97. The company had a trading volume of 7,195,994 shares, compared to its average volume of 1,138,030. Blueprint Medicines Co. has a 52 week low of $73.04 and a 52 week high of $128.51. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market cap of $8.26 billion, a PE ratio of -118.49 and a beta of 0.84. The business has a 50-day simple moving average of $95.59 and a 200-day simple moving average of $95.88.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The firm had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. During the same quarter last year, the business posted $1.40 earnings per share. The firm's revenue for the quarter was up 55.5% compared to the same quarter last year. Research analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.